GRAIL, Inc. (GRAL) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-03-12

How it makes money

It earns revenue by selling the Galleri multi-cancer early detection test to healthcare systems and employers, having processed over 800,000 tests to date.

Revenue is primarily generated through the sale of Galleri, a blood-based test that screens for multiple cancer types by identifying a signal and its origin. The company sells to healthcare systems, employers, and life insurance providers who utilize the test to supplement standard screenings.

Profitability depends on test volume and commercial partnerships. While it processes a high volume of tests, the company remains loss-making as it prioritizes clinical validation over immediate margins.

What protects it: the moat

The business relies on its methylation platform and a clinical database containing data from over 385,000 participants to identify specific organ or tissue types.

The company claims a competitive advantage rooted in the scale of its genomic database, which it believes is the largest of its kind. This database allows the Galleri test to accurately predict the Cancer Signal of Origin with high positive predictive values.

This clinical foundation acts as a barrier to entry, as a rival would need to conduct massive, multi-year studies to match the level of validation required for population-scale cancer screening.

What growth costs

The company incurred a $408.4 million net loss in 2025 while funding large-scale clinical studies and its methylation platform development.

The company must reinvest heavily in research and development to maintain its methylation platform and expand its precision oncology portfolio. These costs, alongside the expenses of conducting massive trials like PATHFINDER 2, led to significant net losses in recent years.

Future spending is focused on securing FDA pre-market approval and establishing broad insurance reimbursement, which requires maintaining extensive laboratory capacity and commercial infrastructure.

What could damage it

Failure to secure FDA pre-market approval or broad insurance reimbursement could permanently impair earnings if clinical data fails to meet primary endpoints.

Earnings are vulnerable to regulatory and payor rejection. While the Galleri test is currently available, its long-term viability depends on moving beyond private partnerships to broad population screening.

A primary endpoint of statistically significant reduction in combined stage 3 and 4 cancer diagnoses was not observed in its largest trial. If future results do not satisfy regulators, the company may never achieve the reimbursement levels needed for a sustainable business model.

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.

Other companies in Diagnostics & Research